Verdiperstat Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 370

Clinical Trials

Multiple clinical trials spanning Phase 1 through Phase 3, early exploratory research, and expanded access protocols evaluate verdiperstat in healthy volunteers and patients with neurodegenerative conditions, including Multiple System Atrophy (cerebellar and parkinsonian variants), Amyotrophic Lateral Sclerosis (ALS), and Semantic Dementia. Featuring both active and completed recruitment statuses, these studies encompass Phase 3 trials and platform regimens for ALS. Sponsorship includes pharmaceutical companies such as Biohaven Pharmaceuticals and AstraZeneca, alongside academic and federal institutions including Brigham and Women's Hospital and the National Institutes of Health.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04297683	ACTIVE_NOT_RECRUITING	Amyotrophic Lateral Sclerosis	Merit E. Cudkowicz, MD	2020-06-14	PHASE2; PHASE3
NCT05184569	ACTIVE_NOT_RECRUITING	Semantic Dementia	Peter Ljubenkov, MD	2022-04-14	PHASE1
NCT04436510	COMPLETED	Amyotrophic Lateral Sclerosis	Merit E. Cudkowicz, MD	2020-07-28	PHASE2; PHASE3
NCT05184569	Recruiting	Semantic Dementia	Peter Ljubenkov MD\|National Institutes of Health (NIH)\|Alzheimer''s Association\|National Institute on Aging (NIA)\|University of California San Francisco	2022-04-14	Phase 1
NCT04616456	COMPLETED	Multiple System Atrophy; Multiple System Atrophy, Cerebellar Variant; Multiple System Atrophy, Parkinson Variant (Disorder); Multiple System Atrophy (MSA) With Orthostatic Hypotension	Brigham and Women's Hospital	2020-12-30	EARLY_PHASE1
NCT03952806	COMPLETED	Multiple System Atrophy	Biohaven Pharmaceuticals, Inc.	2019-07-29	PHASE3
NCT00914303	Completed	Healthy	AstraZeneca	2009-06	Phase 1

(data from https://clinicaltrials.gov, updated on 2026-07-21)

Check the Verdiperstat product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Verdiperstat is a selective, orally active, and irreversible inhibitor of myeloperoxidase (MPO) with an IC50 of 630 nM that targets the active site of the enzyme to block the generation of hypochlorous acid and reactive oxygen species. By suppressing toxic microglial activation and reducing oxidative stress within neural tissue, this inhibition protects neurons from chronic neuroinflammation and slows disease progression in neurodegenerative conditions such as Multiple System Atrophy and Amyotrophic Lateral Sclerosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).